Rich et al., 2011 - Google Patents
Survey of the 2009 commercial optical biosensor literatureRich et al., 2011
- Document ID
- 16560207888354595773
- Author
- Rich R
- Myszka D
- Publication year
- Publication venue
- Journal of Molecular Recognition
External Links
Snippet
We took a different approach to reviewing the commercial biosensor literature this year by inviting 22 biosensor users to serve as a review committee. They set the criteria for what to expect in a publication and ultimately decided to use a pass/fail system for selecting which …
- 230000003287 optical 0 title abstract description 9
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rich et al. | Survey of the 2009 commercial optical biosensor literature | |
Rich et al. | Survey of the year 2006 commercial optical biosensor literature | |
US20240294662A1 (en) | Human mesothelin chimeric antigen receptors and uses thereof | |
Rich et al. | Survey of the year 2005 commercial optical biosensor literature | |
Lee et al. | Decay of Fc-dependent antibody functions after mild to moderate COVID-19 | |
Rich et al. | Survey of the year 2007 commercial optical biosensor literature | |
Shiakolas et al. | Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions | |
Burnie et al. | The incorporation of host proteins into the external HIV-1 envelope | |
US9803193B2 (en) | Protein screening methods | |
Meertens et al. | The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry | |
Saini et al. | The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1α function through distinct receptor interactions | |
Claireaux et al. | A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike | |
WO2011100841A1 (en) | Pd-1 modulation and uses thereof for modulating hiv replication | |
US10822406B2 (en) | Method for treating chronic intestinal inflammation and inflammatory bowel disease by administering antagonists of Oncostatin-M (OSM) and/or antagonists of OSM receptor-beta (OSMR) | |
JP7186266B2 (en) | Single domain antibodies directed against intracellular antigens | |
US20240369565A1 (en) | Circulating Tumor Cell Enrichment Using Neoepitopes | |
Saitakis et al. | Treatment and relapse prevention of typical and atypical optic neuritis | |
WO2015157561A1 (en) | Specific and unique t cell responses and molecular signatures for treatment and diagnosis of mycobacterium tuberculosis | |
Barasa et al. | Development of LB244, an irreversible STING antagonist | |
Labriola et al. | Peptide–antibody fusions engineered by phage display exhibit an ultrapotent and broad neutralization of SARS-CoV-2 variants | |
WO2021097074A1 (en) | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury | |
Haußner et al. | Peptide Paratope Mimics of the Broadly Neutralizing HIV‐1 Antibody b12 | |
JP6908710B2 (en) | Chimeric antigen receptor (CAR) targeting the chemokine receptor CCR4 and its use | |
Warszawski et al. | Design of a basigin‐mimicking inhibitor targeting the malaria invasion protein RH5 | |
Shiakolas et al. | Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions |